- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Plimack Recaps 2017 Immunotherapy Approvals in Bladder Cancer
December 1st 2017, 12:12am
It has been a landmark year for immunotherapy in bladder cancer with the approval of 5 checkpoint inhibitors across first and second line.
Immunotherapy Combinations on the Rise for RCC
November 30th 2017, 7:12am
The combination of PD-1 or PD-L1 inhibitors with existing frontline therapies could represent a superior approach for some treatment-naïve patients with renal cell carcinoma.
Plethora of Ongoing Trials Explore Immunotherapy Combinations for Bladder Cancer
November 30th 2017, 6:11am
Stemming from the wave of checkpoint inhibitor approvals, multiple trials have begun evaluating immunotherapies in combination with other agents for the treatment of patients with advanced bladder cancer.
Dr. Plimack on Frontline Checkpoint Inhibitors in Bladder Cancer
November 30th 2017, 4:20am
Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses checkpoint inhibitors in the frontline setting of bladder cancer.
Dr. McDermott on Nivolumab Plus Ipilimumab in RCC
November 30th 2017, 4:20am
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in renal cell carcinoma (RCC).
Immunotherapy Combo Regimens Next Step in Bladder Cancer
November 30th 2017, 3:27am
Elizabeth Plimack, MD, discusses the impact of the immunotherapy approvals in the first- and second-line setting for bladder cancer and the future of combinations for these patients.
Optimizing Adjuvant Therapy in Renal Cell Carcinoma
November 20th 2017, 1:42am
Patients with high-risk renal cell carcinoma who harbor early systemic dissemination with very poor survival prognosis may derive some benefit from adjuvant therapy.
Immunotherapy Continues to Shape Future Bladder Cancer Paradigm
November 20th 2017, 1:40am
Maria De Santis, MD, discusses the findings of KEYNOTE-045 and the future of immunotherapy in the treatment landscape of bladder cancer.
Dr. Capitanio Discusses Adjuvant Therapy for High-Risk Kidney Cancer
November 19th 2017, 9:50pm
Umberto Capitanio, MD, FEBU, department of Urology, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases.
Dr. Powles on the Impact of Immunotherapy in Kidney Cancer
November 19th 2017, 9:37pm
Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer.
Next Steps in Bladder Cancer to Include Combination Immunotherapy
November 19th 2017, 3:08am
Andrea Necchi, MD, discusses the evolution of bladder cancer therapies, the challenge with the currently available agents, and the next steps and clinical trials being conducted in the field.
Molecular Subtypes Prognostic for OS, DFS in Clear-Cell RCC
November 18th 2017, 10:56pm
Four molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with striking differences seen in overall survival and disease-free survival between each of the groups.
Dr. Junker on Need to Identify Biomarkers to Predict Response to RCC Treatment
November 18th 2017, 8:05pm
Kerstin Junker, MD, associate professor, Department of Urology, Universit
Dr. Mason on the Significance of the PROTECT Study in Prostate Cancer
November 18th 2017, 7:37pm
Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in prostate cancer during the 2017 EMUC Congress.
LDH a Predictor for OS in mCRPC Following Radium-223
November 18th 2017, 4:29am
Log LDH was the strongest predictor for overall survival with radium-223 for men with metastatic castration resistant prostate cancer.
Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC
November 18th 2017, 3:44am
An extension in overall survival seen with the combination of nivolumab and ipilimumab has completely changed the standard of care for patients with metastatic renal cell carcinoma.
Dr. Volpe Discusses the Management of Localized Kidney Cancer
November 18th 2017, 3:13am
Alessandro Volpe, MD, University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy, discusses the management of locally advanced kidney cancer.
Pembrolizumab, Atezolizumab New Standards for Bladder Cancer
November 18th 2017, 2:23am
A wealth of new clinical trial data for immune checkpoint inhibitors has recently been reported for the treatment of patients with metastatic muscle-invasive urothelial carcinoma.
Combining Partial Metastasectomy With Systemic Treatment Beneficial in mRCC
November 18th 2017, 1:41am
The addition of incomplete metastasectomy to systemic therapy improved median overall survival by 3 months in patients with metastatic renal cell carcinoma.
PI-RADS Offers Prognostic Advantage Over mpMRI Alone for Prostatectomy
November 17th 2017, 9:40pm
Use of the novel prostate imaging reporting and data system enhanced the ability to determine prostate cancer stage versus standard multiparametric MRI alone, offering advantages for deciding the extent of resection needed during an endoscopic radical prostatectomy.